A NETWORK META-ANALYSIS OF FIRST-LINE SYSTEMIC THERAPIES FOR ADVANCED HEPATOCELLULAR CARCINOMA

被引：0
|
作者：
Singh, B. [1 ]
Sharma, A. [1 ]
Rai, P. [1 ]
Kaur, G. [1 ]
Pandey, S. [1 ]
机构：
[1] Pharmacoevidence, Sas Nagar Mohali, PB, India
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CO67
引用
收藏
页码：S26 / S26
页数：1
相关论文
共 50 条
  • [41] Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis
    Boutros, Andrea
    Tanda, Enrica Teresa
    Croce, Elena
    Catalano, Fabio
    Ceppi, Marcello
    Bruzzone, Marco
    Cecchi, Federica
    Arecco, Luca
    Fraguglia, Matteo
    Pronzato, Paolo
    Genova, Carlo
    Del Mastro, Lucia
    Lambertini, Matteo
    Spagnolo, Francesco
    EUROPEAN JOURNAL OF CANCER, 2023, 188 : 64 - 79
  • [42] COMPARISON OF FIRSTLINE SYSTEMIC THERAPIES FOR ADVANCED HEPATOCELLULAR CARCINOMA: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
    Hur, Moon Haeng
    Park, Youngsu
    Ko, Yunmi
    Shin, Hyunjae
    Park, Jeayeon
    Kim, Ju Yeon
    Lee, Yun Bin
    Yu, Su Jong
    Kim, Yoon Jun
    Yoon, Jung-Hwan
    Lee, Jeong-Hoon
    HEPATOLOGY, 2023, 78 : S1821 - S1821
  • [43] A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma
    Heo, Ji Haeng
    Park, Chanhyun
    Ghosh, Somraj
    Park, Sun-Kyeong
    Zivkovic, Marko
    Rascati, Karen L.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2021, 46 (01) : 35 - 49
  • [44] Network meta-analysis (NMA) of lenvatinib vs key comparators in first-line unresectable hepatocellular carcinoma (uHCC)
    Trueman, D.
    Ndirangu, K.
    Paine, A.
    Pilkington, H.
    ANNALS OF ONCOLOGY, 2023, 34 : S615 - S616
  • [45] Efficacy and safety of first-line immune checkpoint inhibitor combination therapies in patients with advanced esophageal squamous cell carcinoma: a network meta-analysis
    Wang, Chenglong
    Cai, Tongze
    Wei, Jiangcun
    Huang, Ying
    Xiao, Lin
    Li, Tong
    Qin, Zujie
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [46] Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
    Wang, Shijie
    Wang, Yiting
    Yu, Jiangtao
    Wu, Huaxing
    Zhou, Yanming
    CANCERS, 2022, 14 (22)
  • [47] Efficacy and safety of second-line therapies for advanced hepatocellular carcinoma: a network meta-analysis of randomized controlled trials
    Lu, Fenping
    Zhao, Kai
    Ye, Miaoqing
    Xing, Guangyan
    Liu, Bowen
    Li, Xiaobin
    Ran, Yun
    Wu, Fenfang
    Chen, Wei
    Hu, Shiping
    BMC CANCER, 2024, 24 (01)
  • [48] Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis
    Keiichiro Mori
    Hadi Mostafaei
    Noriyoshi Miura
    Pierre I. Karakiewicz
    Stefano Luzzago
    Manuela Schmidinger
    Andreas Bruchbacher
    Benjamin Pradere
    Shin Egawa
    Shahrokh F. Shariat
    Cancer Immunology, Immunotherapy, 2021, 70 : 265 - 273
  • [49] Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis
    Mori, Keiichiro
    Mostafaei, Hadi
    Miura, Noriyoshi
    Karakiewicz, Pierre, I
    Luzzago, Stefano
    Schmidinger, Manuela
    Bruchbacher, Andreas
    Pradere, Benjamin
    Egawa, Shin
    Shariat, Shahrokh F.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (02) : 265 - 273
  • [50] The cost-effectiveness of new first-line therapies approved in advanced hepatocellular carcinoma
    Giuliani, Jacopo
    Mantoan, Beatrice
    Bonetti, Andrea
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (02) : 434 - 437
12345